{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T03:20:43Z","timestamp":1764645643464,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T00:00:00Z","timestamp":1660435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["NV19-08-00525"],"award-info":[{"award-number":["NV19-08-00525"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer with a highly unfavorable prognosis. Aims: Retrospective statistical analysis of patients with HCC in the field of liver cirrhosis treated at our center from the perspective of demography, and the effects of key changes in diagnostic and therapeutic procedures in the last 10 years on overall survival (OS) and earlier diagnosis. Materials and Methods: This study included 170 cirrhotic patients with HCC (136 men, 80%). Demographic and etiological factors and OS were analyzed based on distribution into three groups according to the period and key changes in diagnostic and therapeutic approaches (BCLC classification staging; standardization of protocol for transarterial chemoembolization (TACE) and the introduction of direct-acting antivirals (DAA) for the treatment of chronic viral hepatitis C (HCV); expansion of systemic oncological therapy). Results: The mean age at the time of diagnosis was 69.3 years (SD = 8.1), and etiology was as follows: non-alcoholic steatohepatitis (NASH) 39%, alcoholic liver disease (ALD) 36%, HCV 18%, cryptogenic liver cirrhosis 3%, chronic hepatitis B infection (HBV) 2%, and other etiology 2%. Distribution of stages according to the BCLC: 0 + A 36%, B 31%, C 22%, and D 11%. However, the distribution in the first studied period was as follows: 0 + A 15%, B 34%, C 36%, and D 15%; and in the last period: 0 + A 45%, B 27%, C 17%, and D 11%, and difference was statistically significant (p &lt; 0.05). The median OS for stages 0 + A, B, C, and D was 58, 19, 6, and 2 months, respectively. During the monitored period, there was a visible increase in the etiology of ALD from 30% to 47% and a decrease in HCV from 22% to 11%. In patients treated with TACE (stage B), the median OS grew from 10 to 24 months (p &lt; 0.0001) between the marginal monitored periods. Conclusions: We described a decreasing number of patients with HCV-related HCC during follow-up possibly linked with the introduction of DAA. In our cohort, an improvement in early-stage diagnosis was found, which we mainly concluded as a result of proper ultrasound surveillance, the institution of a HCV treatment center, and increased experience of our sonographers with an examination of cirrhotic patients. Lastly, we described significantly improved overall survival in patients with intermediate HCC treated by TACE, due to the increased experience of interventional radiologists with the method at our facility and an earlier switch to systemic therapy in case of non-response to TACE.<\/jats:p>","DOI":"10.3390\/medicina58081099","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T03:33:20Z","timestamp":1660534400000},"page":"1099","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Etiopathogenetic Factors of Hepatocellular Carcinoma, Overall Survival, and Their Evolution over Time\u2014Czech Tertiary Center Overview"],"prefix":"10.3390","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8090-4389","authenticated-orcid":false,"given":"Petr","family":"H\u0159\u00edbek","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, 1st Faculty of Medicine, Charles University and Military University Hospital Prague, 169 02 Prague, Czech Republic"},{"name":"Department of Internal Medicine, Faculty of Military Health Sciences, University of Defense, 500 02 Hradec Kralove, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johana","family":"Klasov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, 1st Faculty of Medicine, Charles University and Military University Hospital Prague, 169 02 Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"T\u016fma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Military Health Sciences, University of Defense, 500 02 Hradec Kralove, Czech Republic"},{"name":"Department of Radiodiagnostic, Military University Hospital Prague, 169 02 Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"Kupsa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Military Health Sciences, University of Defense, 500 02 Hradec Kralove, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Urb\u00e1nek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, 1st Faculty of Medicine, Charles University and Military University Hospital Prague, 169 02 Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cgh.2016.07.033","article-title":"Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance","volume":"15","author":"Khalaf","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1002\/lt.22365","article-title":"Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience","volume":"17","author":"Mazzaferro","year":"2011","journal-title":"Liver Transpl."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: The BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin. Liver Dis."},{"key":"ref_4","unstructured":"European Association for the Study of The Liver (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"ref_7","first-page":"83","article-title":"Doporu\u010den\u00fd postup pro l\u00e9\u010dbu a diagnostiku hepatocelul\u00e1rn\u00edho karcinomu","volume":"66","author":"Bruha","year":"2012","journal-title":"Gastroent. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/CH-211309","article-title":"Hepatocellular carcinoma in the non-cirrhotic liver","volume":"80","author":"Dong","year":"2022","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5114\/ceh.2021.104631","article-title":"Clinical aspects and treatment of hepatocellular carcinoma in north- eastern Poland","volume":"7","author":"Tarasik","year":"2021","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2016.11.020","article-title":"Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012","volume":"152","author":"White","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_11","unstructured":"Du\u0161ek, L. (2022, May 02). Epidemiologie Zhoubn\u00fdch N\u00e1dor\u016f v \u010cesk\u00e9 Republice. Available online: http:\/\/www.svod.cz."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"12197","DOI":"10.3748\/wjg.v21.i42.12197","article-title":"Hepatocellular carcinoma in the elderly: Meta-analysis and systematic literature review","volume":"21","author":"Hung","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: A systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Rabekova, Z., Frankova, S., Jirsa, M., Neroldova, M., Lunova, M., Fabian, O., and Sperl, J. (2021). Alpha-1 Antitrypsin and Hepatocellular Carcinoma in Liver Cirrhosis: SERPINA1 MZ or MS Genotype Carriage Decreases the Risk. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910560"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/JHC.S221187","article-title":"Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment","volume":"7","author":"Dash","year":"2020","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"Llovet","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jhep.2009.09.004","article-title":"Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: A randomized phase III trial","volume":"51","author":"Okusaka","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): A randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41416-018-0103-0","article-title":"Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study","volume":"119","author":"Chau","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin. Liver Dis."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/8\/1099\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:08:33Z","timestamp":1760141313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/8\/1099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,14]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["medicina58081099"],"URL":"https:\/\/doi.org\/10.3390\/medicina58081099","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2022,8,14]]}}}